Related Experiment Video
Updated: Jun 29, 2025

Intratracheal Inoculation of Fischer 344 Rats with Francisella tularensis
Published on: September 30, 2017
Development, Strategies, and Challenges for Tularemia Vaccine
Safoura Moradkasani1,2, Max Maurin3, Amir Salek Farrokhi4
1National Reference Laboratory for Plague, Tularemia and Q Fever, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Akanlu, KabudarAhang, Hamadan, Iran.
Abstract:
Francisella tularensis is a facultative intracellular bacterial pathogen that affects both humans and animals. It was developed into a biological warfare weapon as a result. In this article, the current status of tularemia vaccine development is presented. A live-attenuated vaccine that was designed over 50 years ago using the less virulent F. tularensis subspecies holarctica is the only prophylactic currently available, but it has not been approved for use in humans or animals. Other promising live, killed, and subunit vaccine candidates have recently been developed and tested in animal models. This study will investigate some possible vaccines and the challenges they face during development.

